|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|
| Revenue | ||
| Revenue | ||
| Assay services revenue | ||
| Product revenue | ||
| Other revenue | ||
| Collaboration revenue | ||
| Other revenue | ||
| Other revenue | ||
| Total other revenue | ||
| Total revenue | ||
| Operating expenses | ||
| Cost of revenue | ||
| Assay services revenue | ||
| Product revenue | ||
| Research and development | ||
| Selling, general and administrative | ||
| Total operating expenses | ||
| Loss from operations | ||
| Other income (expense) | ||
| Interest income and other, net | ||
| Interest expense | ||
| Change in fair value of warrant liabilities | ||
| Change in fair value of earn-out liability | ||
| Loss on extinguishment of debt, net | ||
| Total other income (expense) | ||
| Net loss before income tax benefit (provision) | ||
| Income tax expense (benefit) | ||
| Net loss | ||
| Other comprehensive loss | ||
| Net unrealized loss on available-for-sale securities | ||
| Foreign currency translation loss | ||
| Total other comprehensive loss | ||
| Comprehensive loss | ||
| Net loss per share, basic (in dollars per share) | ||
| Net loss per share, diluted (in dollars per share) | ||
| Weighted-average shares used in computing net loss per share, basic (in shares) | ||
| Weighted-average shares used in computing net loss per share, diluted (in shares) |
Loading...
